When mixing an additional immune checkpoint blocking drug to existing therapies, the scientists observed that tumors shrunk “in lab models of treatment-resistant melanoma.” Specifically, the researchers blocked PD-1, LAG-3 and TIM-3. This “helped restore immune function and led to complete tumor regressions in some cases.” The treatment proved to be safe.
Additional study findings discovered that patients who have immunotherapy resistant melanoma tend to have more TIM-3.
